Clinical Trials Browser

Phase 1/2 × anlotinib × Tumor-Agnostic × Clear all

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Phase 1/2 Not yet recruiting

Neoplasms